Valneva SE, a specialty vaccine company, announced today the publication of full data from the Phase 1 clinical trial of its chikungunya vaccine candidate, VLA1553, in the peer-reviewed medical journal The Lancet Infectious Diseases.
The Lancet paper provides a detailed analysis of final Phase 1 results and supports the continued clinical development of VLA1553.
Wolfgang Bender, Ph.D., M.D., Chief Medical Officer of Valneva, commented, “We reported excellent Phase 1 results for our single-shot chikungunya vaccine and we’re pleased that these important results are now fully available to the broader infectious disease community. Millions of people have been affected by chikungunya and our objective is to help address this ongoing public health crisis as soon as we can.”
Valneva has previously reported the successful outcome of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in February 2020 and is now preparing to initiate Phase 3 clinical studies in the U.S. later this year.
Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), a Togaviridae virus, transmitted by Aedes mosquitoes. Clinical symptoms include acute onset of fever, debilitating joint and muscle pain, headache, nausea and rash, potentially developing into long-term, serious health impairments.
- COVID-19: Japan approves saliva PCR test
- Salmonella outbreak affects more than 200 in Hong Kong
- Australia: Hendra virus confirmed in New South Wales horse
- Kansas State University: Research team receives $11.3 million COBRE grant to establish infectious disease research center
- Coronavirus chat on NEWS TALK with Brandon and Bob
- COVID-19 research: Postoperative death, Pulmonary embolism
- SARS-CoV-2: Researchers map infection in cells of respiratory tract
- Singapore dengue and COVID-19 updates